Skip to main content
Press release April 24, 2026

Cost Comparison Analysis of Hospitalizations for Vadadustat Versus Darbepoetin Alfa Based on the INNO2VATE Trials

Akebia Therapeutics, Inc. (AKBA)

© 2026 Akebia Therapeutics. All rights reserved. AURYXIA®, AKEBIA® Therapeutics and their associated logos are trademarks of Akebia and/or its affiliates. All other trademarks and registered trademarks, trade names and service marks referred to herein are the property of their respective owners. Akebia is not associated with or sponsored by the trademark owners. Terms of Use / Privacy Policy / Social Media Guidelines / Note Regarding Forward Looking Statements / Website by D&CO
View original release